Brain Advance Access originally published online on May 4, 2005
Brain 2005 128(7):1498-1510; doi:10.1093/brain/awh510
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease
1 Dalhousie University and Queen Elizabeth II Health Science Center, Division of Neurosurgery and Neuroscience, Halifax, 2 McGill University and Montreal Neurological Institute, McConnel Brain Imaging Centre, Montreal, Canada and 3 Harvard University and McLean Hospital, NINDS Udall Parkinson's Disease Research Center of Excellence, Belmont, MA, USA
Correspondence to: Professor Ole Isacson, Neuroregeneration Laboratory, Harvard Medical School, McLean Hospital, MRC 130, 115 Mill St, Belmont, MA 02478, USA E-mail: isacson{at}hms.harvard.edu
We report the first post-mortem analysis of two patients with Parkinson's disease who received fetal midbrain transplants as a cell suspension in the striatum, and in one case also in the substantia nigra. These patients had a favourable clinical evolution and positive 18F-fluorodopa PET scans and did not develop motor complications. The surviving transplanted dopamine neurons were positively identified with phenotypic markers of normal control human substantia nigra (n = 3), such as tyrosine hydroxylase, G-protein-coupled inward rectifying current potassium channel type 2 (Girk2) and calbindin. The grafts restored the cell type that provides specific dopaminergic innervation to the most affected striatal regions in the parkinsonian brain. Such transplants were able to densely reinnervate the host putamen with new dopamine fibres. The patients received only 6 months of standard immune suppression, yet by post-mortem analysis 3–4 years after surgery the transplants appeared only mildly immunogenic to the host brain, by analysis of microglial CD45 and CD68 markers. This study demonstrates that, using these methods, dopamine neuronal replacement cell therapy can be beneficial for patients with advanced disease, and that changing technical approaches could have a favourable impact on efficacy and adverse events following neural transplantation.
Key Words: transplantation; dopamine neuron; Parkinson's disease
Abbreviations: 18F-DOPA = 18F-fluorodopa; GDNF = glial-derived neurotrophic factor; GFAP = glial fibrillary acidic protein; Girk2 = G-protein-coupled inward rectifying current potassium channel type 2; PBS = phosphate buffered saline; SN = substantia nigra; SNc = substantia nigra pars compacta; TH = tyrosine hydroxylase; UPDRS = Unified Parkinson's Disease Rating Scale
Received August 4, 2004. Revised November 12, 2004. Second revision on February 9, 2005. Third revision on March 11, 2005. Accepted March 14, 2005.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Ma, C. Tang, T. Chaly, P. Greene, R. Breeze, S. Fahn, C. Freed, V. Dhawan, and D. Eidelberg Dopamine Cell Implantation in Parkinson's Disease: Long-Term Clinical and 18F-FDOPA PET Outcomes J. Nucl. Med., January 1, 2010; 51(1): 7 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joksimovic, A. Anderegg, A. Roy, L. Campochiaro, B. Yun, R. Kittappa, R. McKay, and R. Awatramani Spatiotemporally separable Shh domains in the midbrain define distinct dopaminergic progenitor pools PNAS, November 10, 2009; 106(45): 19185 - 19190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Farag, H. V. Vinters, and J. Bronstein Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease Neurology, October 6, 2009; 73(14): 1095 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Friling, E. Andersson, L. H. Thompson, M. E. Jonsson, J. B. Hebsgaard, E. Nanou, Z. Alekseenko, U. Marklund, S. Kjellander, N. Volakakis, et al. Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells PNAS, May 5, 2009; 106(18): 7613 - 7618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Lees The Parkinson chimera Neurology, February 17, 2009; 72(7_Supplement_2): S2 - S11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Winner, D. M. Vogt-Weisenhorn, C. D. Lie, I. Blumcke, and J. Winkler Review: Cellular repair strategies in Parkinson's disease Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 51 - 60. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Vinuela, P. J. Hallett, C. Reske-Nielsen, M. Patterson, T. D. Sotnikova, M. G. Caron, R. R. Gainetdinov, and O. Isacson Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease Brain, December 1, 2008; 131(12): 3361 - 3379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mukhida, M. Hong, G.B. Miles, T. Phillips, B.A. Baghbaderani, M. McLeod, N. Kobayashi, A. Sen, L.A. Behie, R.M. Brownstone, et al. A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats Brain, August 1, 2008; 131(8): 2106 - 2126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sanchez-Pernaute, H. Lee, M. Patterson, C. Reske-Nielsen, T. Yoshizaki, K. C. Sonntag, L. Studer, and O. Isacson Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease Brain, August 1, 2008; 131(8): 2127 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wernig, J.-P. Zhao, J. Pruszak, E. Hedlund, D. Fu, F. Soldner, V. Broccoli, M. Constantine-Paton, O. Isacson, and R. Jaenisch Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease PNAS, April 15, 2008; 105(15): 5856 - 5861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. E. O'Keeffe, S. A. Scott, P. Tyers, G. W. O'Keeffe, J. W. Dalley, R. Zufferey, and M. A. Caldwell Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease Brain, March 1, 2008; 131(3): 630 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K Ormerod, T. D Palmer, and M. A Caldwell Neurodegeneration and cell replacement Phil Trans R Soc B, January 12, 2008; 363(1489): 153 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Guzman, N. Uchida, T. M. Bliss, D. He, K. K. Christopherson, D. Stellwagen, A. Capela, J. Greve, R. C. Malenka, M. E. Moseley, et al. Long-term monitoring of transplanted human neural stem cells in developmental and pathological contexts with MRI PNAS, June 12, 2007; 104(24): 10211 - 10216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. A. de Bie, R. M. Gladstone, A. P. Strafella, J.-H. Ko, and A. E. Lang Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse Arch Neurol, June 1, 2007; 64(6): 886 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Breysse, T. Carlsson, C. Winkler, A. Bjorklund, and D. Kirik The Functional Impact of the Intrastriatal Dopamine Neuron Grafts in Parkinsonian Rats Is Reduced with Advancing Disease J. Neurosci., May 30, 2007; 27(22): 5849 - 5856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yasuhara, N. Matsukawa, K. Hara, G. Yu, L. Xu, M. Maki, S. U. Kim, and C. V. Borlongan Transplantation of Human Neural Stem Cells Exerts Neuroprotection in a Rat Model of Parkinson's Disease J. Neurosci., November 29, 2006; 26(48): 12497 - 12511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Soundararajan, G. B. Miles, L. L. Rubin, R. M. Brownstone, and V. F. Rafuse Motoneurons derived from embryonic stem cells express transcription factors and develop phenotypes characteristic of medial motor column neurons. J. Neurosci., March 22, 2006; 26(12): 3256 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Johansson, I-H. Lee, L. Olson, and C. Spenger Olfactory ensheathing glial co-grafts improve functional recovery in rats with 6-OHDA lesions Brain, December 1, 2005; 128(12): 2961 - 2976. [Abstract] [Full Text] [PDF]
|
|